Covid-19 intellectual property pool gaining support
While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...
The Expanding Reach of the European Patent Office. Good for Health?
The European Patent Office (EPO) is tasked with the examination of patent applications and the granting of patents when these applications meet the patentability...
Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
Uganda tells ARIPO: No more patents for pharmaceuticals
Uganda has notified the African Regional Intellectual Property Organisation (ARIPO) that pharmaceutical inventions are not eligible for patentability in the country, Managing IP reported.
With...
Corbyn’s Compulsory Licenses. Will they work?
On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...
Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Drug Price Transparency Calls Move from South Africa to World Health Assembly
by Katrina Perehudoff and Jennifer Sellin
Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...